Maprotiline chemical structure of maprotiline
Find information on thousands of medical conditions and prescription drugs.

Maprotiline

more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
Macrodantin
Maprotiline
Marcaine
Marezine
Marijuana
Marinol
Marplan
Matulane
Maxair
Maxalt
Maxolon
MDMA
Measurin
Mebendazole
Mebendazole
Meclofenoxate
Medrol
Mefenamic acid
Mefloquine
Melagatran
Melarsoprol
Meloxicam
Melphalan
Memantine
Metadate
Metamfetamine
Metamizole sodium
Metandienone
Metaxalone
Metenolone
Metformin
Methadone
Methamphetamine
Methaqualone
Metharbital
Methcathinone
Methenamine
Methionine
Methocarbamol
Methohexital
Methotrexate
Methotrexate
Methoxsalen
Methylcellulose
Methyldopa
Methylergometrine
Methylin
Methylphenidate
Methylphenobarbital
Methylprednisolone
Methyltestosterone
Methysergide
Metiamide
Metoclopramide
Metohexal
Metoprolol
Metrogel
Metronidazole
Metyrapone
Mobic
Moclobemide
Modafinil
Modicon
Monopril
Montelukast
Motrin
Moxidectin
Moxifloxacin
Moxonidine
MS Contin
Mucinex
Mucomyst
Mupirocin
Mupirocin
Muse
Mycitracin
Mycostatin
Myfortic
Mykacet
Mykinac
Myleran
Mylotarg
Mysoline
Phentermine
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology

Maprotiline (sold as Deprilept®, Ludiomil®, Psymion®) is a tetracyclic antidepressant. It is a stong norepinephrine reuptake inhibitor with only weak effects on serotonin and dopamine reuptake.

It exerts blocking effects at the following postsynaptic receptors:

  • Strong : alpha1
  • Moderate : 5-HT2, muscarinic, H1, D2
  • Weak : alpha2
  • Extremely weak : 5-HT1

The pharmacologic profile of Maprotiline explains its antidepressant, sedative, anxiolytic, sympatholytic, and anticholinergic activities. Additionally, it shows a strong antagonism against Reserpine-induced effects in animal studies, as the other 'cassical' antidepressants do. Although Maprotiline behaves in most regards as a 'first generation antidepressant' it is commonly referred to as 'second generation antidepressant'.

Sedation has a fast onset (the same day), while remission of the depression itself is noted usually after a latent period of 1 to 4 weeks.

Maprotiline does not brighten up the mood in nondepressed persons.

History

Maprotiline was developed and has been marketed by the Swiss manufacturer Geigy (now Novartis) since the early 1980's under the brand name Ludiomil®. Generics are widely available.

Indications

  • Treatment of depressions of all forms and severities (endogenous, psychotic, involutional, and neurotic)
  • Treatment of the depressive phase in bipolar depression
  • For the symptomatic relief of anxiety, tension or insomnia

N.B. The use of Maprotiline in the treatment of Enuresia in pediatric patients has so far not been systemetically explored and its use can therefore not be recommended.

Contraindications

Absolute

  • Hypersensitivity to Maprotiline or to other tri-/tetracyclic antidepressants
  • Hypertrophy of the prostate gland with urine hesitancy
  • Closed Angle Glaucoma

Special caution needed

  • Concomitant treatment with a MAO-Inhibitor
  • Serious impairment of liver and kidney function
  • Epilepsy and other conditions that lower the seizure threshold (active brain tumors, alcohol withdrawal, other medications)
  • Serious cardiovascular conditions (arrhythmias, heart insufficience, state after myocardial infarction etc.)
  • Treatment of patients under age 18

Pregnancy and nursing

If you are pregnant or thinking of becoming pregnant, before taking this medicine talk to your doctor about the benefits versus the risks to your pregnancy. Animal studies showed delayed bone development. Use this medicine only if it is clearly needed.

Read more at Wikipedia.org


[List your site here Free!]


Depression in the Long-Term Care Setting
From American Family Physician, 5/15/02 by Grace Brooke Huffman

Elderly patients living in the nursing home setting are up to five times more likely to have depression, but fewer than one fourth are adequately treated. Physicians may believe that other medical conditions are causing the depression or that other medical conditions may make treatment of depression contraindicated. In addition, there is little evidence about the optimal treatment of depression in elderly patients. Brown and associates performed a cross-sectional study and describe management of this condition.

A database used by the Health Care Financing Administration (HCFA) was the source of data for this study. All Medicaid and Medicare-certified nursing homes in Kansas, Maine, Mississippi, New York, and South Dakota were included. Medications given to each resident were recorded, and antidepressants were classified as tricyclics (amitriptyline, imipramine, doxepin, amoxapine, protriptyline, nortriptyline, trimipramine, and desipramine), tetracyclic (maprotiline), selective serotonin reuptake inhibitors (fluoxetine, sertraline, paroxetine, and fluvoxamine), monoamine oxidase inhibitors (phenelzine, isocarboxazid, and tranylcypromine), and others (venlafaxine, trazodone, bupropion, and nefazodone).

Of the 428,055 residents included in the study, 46,677 were diagnosed with depression. The diagnosis occurred more often in women than in men and more often in non-Hispanic white patients than those with other ethnic backgrounds. One half (55 percent) of those with this diagnosis received an antidepressant. Many of these patients were given less than the manufacturer's recommended dosage, although the authors acknowledge that some of the antidepressants may have been prescribed for indications other than depression.

Patients who were 85 years of age or older were less likely to be given treatment than younger patients, and blacks were less likely to be given treatment than whites. Patients with cancer or more than six diagnosed clinical conditions were less likely to take antidepressants. On the other hand, patients with diabetes mellitus or cerebrovascular disease were more likely to receive antidepressants.

The authors concur with the recommendations of the National Institutes of Health Consensus Development Conference on Diagnosis and Treatment of Depression in Late Life, that elderly patients with depression should be given adequate dosages of antidepressants and continue taking them for an appropriate length of time to maximize the likelihood of recovery. Up to 80 percent of these patients respond well to such treatment.

Physicians should be aware that, in the elderly patient, depression may be difficult to distinguish from other conditions (such as dementia), and patients may present with symptom profiles that are different from those of younger patients. Finally, elderly patients may not have full-blown depression but, in this population, a symptom complex representing subsyndromal depression may be amenable to treatment.

COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2002 Gale Group

Return to Maprotiline
Home Contact Resources Exchange Links ebay